

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

CANCELLATION AND GRANT OF AWARD PURSUANT TO THE SHARE INCENTIVE SCHEME

Reference is made to the announcement of Transcenta Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated August 28, 2026 (the “**Announcement**”), in relation to, among other things, the appointment of Prof. Genhong Cheng (“**Prof. Cheng**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

CANCELLATION OF THE PREVIOUS GRANT

As stated in the Announcement, as part of his remuneration and is to incentivize and retain him, Prof. Cheng has been awarded 30,000 award Shares (the “**Previous Grant**”). To further enhance the Group’s practice in regard to the granting of share incentives, taking into account the fact that none of such award Shares has been transferred to Prof. Cheng, the Previous Grant has been cancelled. Pursuant to the Note to Listing Rule 17.03(14), the cancelled Previous Grant will be regarded as utilised for the purpose of calculating the Scheme Mandate Limit (and the service provider sublimit).

GRANT OF SHARE AWARD

On September 30, 2026, in place of the cancelled Previous Grant, new 30,000 award Shares (the “**New Award Shares**”) under the Share Incentive Scheme were granted to Prof. Cheng (the “**Grant**”).

Following the cancellation of the Previous Grant and the granting of the New Award Shares, as at the date of this announcement, the number of Shares available for future grant after the Grant under the Share Incentive Scheme are set out below: (i) the Scheme Mandate Limit will be 1,281,240 Shares; and (ii) the service provider sublimit will be 1,281,240 Shares (service provider sublimit being subject to the Scheme Mandate Limit).

Details of the Grant are set out below:

Date of grant:	September 30, 2026
Number of award grantee and their name:	One Director, namely Prof. Cheng

Number of New Award Shares granted:	30,000 New Award Shares, representing approximately 0.01% of the total issued share capital of the Company (excluding treasury Shares) as at the date of this announcement
Purchase price of the New Award Shares:	Nil
Closing price of the Shares on the date of grant:	HK\$0.995 per Share
Consideration for the New Award Shares:	Nil
Vesting period of the New Award Shares:	All 30,000 New Award Shares will be vested over three years from the date of grant (i.e. September 30, 2026) pursuant to the terms and conditions of the appointment letter of Prof. Cheng.
Performance targets of the New Award Shares:	There is no performance target attached to the Grant. As Grant forms part of Prof. Cheng remuneration and is to incentivize and retain him, whose contributions are beneficial to the continual operation, development and long-term growth of the Group, the Remuneration Committee is of the view that it is not necessary to set performance targets for the Grant to Prof. Cheng.
Claw-back mechanism of the award Shares:	The key claw-back terms are as follows: If the award grantee ceases to be an eligible person by reason of retirement, any outstanding award Shares and related income not yet vested shall continue to vest in accordance with the vesting dates set out in the award letter, unless the Scheme Administrator determines otherwise at his/her absolute discretion. If the award grantee ceases to be an eligible person by reason of (i) death of the award grantee, (ii) termination of the award grantee's employment or contractual engagement with the Group or an affiliate by reason of his/her permanent physical or mental disablement, (iii) termination of the award grantee's employment or contractual engagement with the Group by reason of redundancy, any outstanding award Shares and related income not yet vested shall be immediately forfeited, unless the Scheme Administrator determines otherwise at their absolute discretion.

REASONS FOR AND BENEFITS OF THE GRANT

The Grant to Prof. Cheng forms part of his remuneration approved by the Remuneration Committee. Such grant will encourage him to work towards enhancing the value of the Company and the Shares for the benefits of the Company and Shareholders as a whole by providing his independent opinion and judgment to the Board in building the strategy and long-term development of the Company. In view of the foregoing, the Grant to Prof. Cheng is made with the view to aligning his interests with those of the Group through ownership of Shares, dividends and other distributions paid on Shares and/or the increase in value of the Shares, and to encouraging and retaining him to make contributions to the long-term growth and profits of the Group.

LISTING RULES IMPLICATIONS

Pursuant to Rule 17.04(1) of the Listing Rules, the Grant to Prof. Cheng, an independent non-executive Director, has been approved by all independent non-executive Directors (apart from Prof. Cheng who did not vote nor had he been counted towards the quorum).

For the avoidance of doubt, the award grantee, i.e., Prof. Cheng, an independent non-executive Director, is not the chief executive or substantial shareholder of the Company, nor is he their respective associates (as defined under the Listing Rules), or a related entity participant or a service provider (as defined under the Listing Rules). No financial assistance has been provided by the Group to him for the purchase of Shares under the Share Incentive Scheme.

Save as disclosed above, all other information as set out in the Announcement remains unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

By Order of the Board
Transcenta Holding Limited
Xueming Qian

Executive Director, Chairman and Chief Executive Officer

Hong Kong, September 30, 2026

As at the date of this announcement, the Board comprises (i) Dr. Xueming Qian as executive Director, chairman and chief executive officer; (ii) Dr. Li Xu and Dr. Han Sen Xu as non-executive Directors; and (iii) Mr. Jiasong Tang, Ms. Helen Wei Chen and Prof. Genhong Cheng as independent non-executive Directors.